Abstract | BACKGROUND: METHODS: Patients with progressive AIPC received 90 mg/m2 paclitaxel by 1-hour intravenous infusion weekly for 3 weeks, followed by a 1-week treatment rest. Patients received 140 mg EMP orally 3 times daily on the day before, the day of, and the day after paclitaxel administration. Patients received 1 mg warfarin daily to prevent thromboembolism. RESULTS: Sixty-six patients with progressive AIPC received treatment at 29 centers. Forty-two percent of patients had a 50% decline in prostate-specific antigen (PSA; 95% confidence interval [CI], 30-54%). For 26 patients with bidimensionally measurable disease, the objective response rate was 15% (95% CI, 1-30%). The median time to disease progression was 6.3 months, and the median time to PSA progression was 11.4 months. The median survival period was 15.6 months. Grade 3-4 toxicities were uncommon and included thromboembolism (8%), anemia (3%), neutropenia (3%), and peripheral neuropathy (2%). There was one treatment-related death. CONCLUSIONS: This regimen of EMP plus weekly paclitaxel was an active and well tolerated treatment for patients with AIPC.
|
Authors | David J Vaughn, Archie W Brown Jr, W Graydon Harker, Sang Huh, Lance Miller, David Rinaldi, Fairooz Kabbinavar |
Journal | Cancer
(Cancer)
Vol. 100
Issue 4
Pg. 746-50
(Feb 15 2004)
ISSN: 0008-543X [Print] United States |
PMID | 14770430
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2004 American Cancer Society. |
Chemical References |
- Androgens
- Estramustine
- Paclitaxel
|
Topics |
- Aged
- Aged, 80 and over
- Androgens
(pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma
(drug therapy, pathology)
- Drug Administration Schedule
- Estramustine
(administration & dosage)
- Humans
- Infusions, Intravenous
- Male
- Middle Aged
- Paclitaxel
(administration & dosage)
- Prostatic Neoplasms
(drug therapy, pathology)
- Survival Analysis
- Treatment Outcome
|